GAINESVILLE, Fla. — July 18, 2011 — Quick-Med Technologies, Inc., a life sciences company that is
developing innovative technologies for the healthcare and consumer markets, announced today that
the Patent Office of the Australian Government has issued another patent to protect the Company’s
intellectual property involving its NIMBUS technology.
The patent titled “Antimicrobial Cationic Polyelectrolyte Coating” covers the process for
non-leachably bonding the NIMBUS active agent to wound dressings and various other substrates. It
has been designated Australian Patent No. 2006283043.
“We are pleased that the patents underlying our NIMBUS intellectual property continue to
issue globally, supporting our efforts to expand into promising international markets,” said Dr.
Jerry Olderman, Quick-Med’s vice president of Research & Development. “NIMBUS is an important
antimicrobial technology for medical devices because it doesn’t leach or suffer depletion, doesn’t
initiate bacterial resistance, doesn’t interfere with tissue healing and prevents odor generation,”
added Dr. Olderman.
NIMBUS technology provides a safe and effective structure for medical applications. This
non-leachable configuration prohibits the depletion of the active polymer during use so that the
product retains its initial high level of performance. Some antimicrobials initiate bacterial
resistance when they are free to migrate and thus enter the bacteria or deplete to a level that is
insufficient to inactivate or destroy the bacteria. Another advantage to using a bound active is
that it doesn’t interfere with wound healing as has been documented for silver containing
dressings. The absorbent part of the dressing, in its action against microorganisms that are drawn
into the dressing, prohibits a build-up of a bacterial population that can cause odor or would be
free to re-enter the wound and contribute to renewal of an infectious environment.
Posted on July 19, 2011
Source: Quick-Med Technologies
